Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 102 | 2024 | 5143 | 5.260 |
Why?
|
Boronic Acids | 32 | 2021 | 914 | 1.730 |
Why?
|
Antineoplastic Agents | 54 | 2023 | 13616 | 1.680 |
Why?
|
Pyrazines | 30 | 2015 | 1199 | 1.320 |
Why?
|
Stromal Cells | 14 | 2019 | 1330 | 1.130 |
Why?
|
Thalidomide | 25 | 2015 | 885 | 1.080 |
Why?
|
Drug Resistance, Neoplasm | 21 | 2023 | 5292 | 0.980 |
Why?
|
Gene Expression Regulation, Neoplastic | 17 | 2021 | 8519 | 0.920 |
Why?
|
Proto-Oncogene Proteins c-myc | 3 | 2021 | 988 | 0.880 |
Why?
|
Cell Line, Tumor | 40 | 2024 | 16945 | 0.760 |
Why?
|
Xenograft Model Antitumor Assays | 15 | 2021 | 3590 | 0.760 |
Why?
|
Cytotoxicity, Immunologic | 4 | 2023 | 1351 | 0.730 |
Why?
|
Proteasome Endopeptidase Complex | 8 | 2021 | 1314 | 0.720 |
Why?
|
Tumor Cells, Cultured | 14 | 2021 | 6128 | 0.690 |
Why?
|
Drug Screening Assays, Antitumor | 9 | 2014 | 716 | 0.680 |
Why?
|
Luminescent Measurements | 2 | 2012 | 342 | 0.660 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2021 | 305 | 0.650 |
Why?
|
Neoplastic Stem Cells | 5 | 2021 | 1347 | 0.620 |
Why?
|
Killer Cells, Natural | 5 | 2023 | 2202 | 0.590 |
Why?
|
Apoptosis | 24 | 2023 | 9468 | 0.510 |
Why?
|
Histone Deacetylase Inhibitors | 8 | 2013 | 774 | 0.510 |
Why?
|
Cell Survival | 16 | 2021 | 5790 | 0.500 |
Why?
|
Embryo, Mammalian | 1 | 2021 | 1674 | 0.480 |
Why?
|
NF-kappa B | 7 | 2024 | 2485 | 0.480 |
Why?
|
Protease Inhibitors | 8 | 2009 | 753 | 0.450 |
Why?
|
Adaptation, Physiological | 1 | 2021 | 1301 | 0.450 |
Why?
|
Mice, SCID | 11 | 2017 | 2625 | 0.450 |
Why?
|
Mice, Inbred NOD | 7 | 2021 | 1824 | 0.440 |
Why?
|
Oligopeptides | 4 | 2018 | 1186 | 0.420 |
Why?
|
Plant Growth Regulators | 1 | 2012 | 50 | 0.410 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2020 | 1517 | 0.410 |
Why?
|
Oxylipins | 1 | 2012 | 53 | 0.410 |
Why?
|
Cyclopentanes | 1 | 2012 | 87 | 0.410 |
Why?
|
Signal Transduction | 20 | 2020 | 23397 | 0.410 |
Why?
|
Hematologic Neoplasms | 4 | 2023 | 1890 | 0.400 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2021 | 1889 | 0.390 |
Why?
|
Ubiquitin-Activating Enzymes | 1 | 2012 | 85 | 0.390 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 23 | 2021 | 11729 | 0.390 |
Why?
|
Thiocyanates | 1 | 2011 | 70 | 0.380 |
Why?
|
Isothiocyanates | 1 | 2011 | 49 | 0.380 |
Why?
|
Depsipeptides | 2 | 2010 | 95 | 0.380 |
Why?
|
Adaptor Proteins, Signal Transducing | 3 | 2021 | 2895 | 0.380 |
Why?
|
Pteridines | 1 | 2011 | 47 | 0.380 |
Why?
|
Acetates | 1 | 2012 | 321 | 0.370 |
Why?
|
Ubiquitin | 2 | 2017 | 838 | 0.370 |
Why?
|
Cyclin-Dependent Kinase 9 | 2 | 2021 | 67 | 0.370 |
Why?
|
Enzyme Inhibitors | 7 | 2014 | 3710 | 0.360 |
Why?
|
Mice | 37 | 2023 | 81402 | 0.350 |
Why?
|
Cyclin-Dependent Kinases | 3 | 2023 | 653 | 0.350 |
Why?
|
Ubiquitins | 1 | 2012 | 366 | 0.350 |
Why?
|
Immunomodulation | 2 | 2013 | 547 | 0.350 |
Why?
|
Coculture Techniques | 6 | 2013 | 1340 | 0.340 |
Why?
|
Stem Cell Transplantation | 5 | 2012 | 1598 | 0.340 |
Why?
|
Paraproteinemias | 4 | 2005 | 248 | 0.340 |
Why?
|
Lactams, Macrocyclic | 6 | 2013 | 318 | 0.330 |
Why?
|
Bone Marrow | 10 | 2018 | 2907 | 0.330 |
Why?
|
Cell Cycle | 10 | 2017 | 2929 | 0.320 |
Why?
|
Tumor Microenvironment | 8 | 2023 | 3874 | 0.320 |
Why?
|
HSP90 Heat-Shock Proteins | 7 | 2013 | 425 | 0.320 |
Why?
|
Polydeoxyribonucleotides | 2 | 2010 | 136 | 0.320 |
Why?
|
Gene Expression Profiling | 11 | 2019 | 9410 | 0.310 |
Why?
|
Benzoquinones | 5 | 2013 | 198 | 0.310 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2012 | 621 | 0.310 |
Why?
|
Imidazoles | 4 | 2013 | 1179 | 0.310 |
Why?
|
Humans | 137 | 2024 | 760437 | 0.310 |
Why?
|
Animals | 45 | 2023 | 168253 | 0.300 |
Why?
|
Bone Neoplasms | 1 | 2020 | 2525 | 0.300 |
Why?
|
Protein Kinase Inhibitors | 7 | 2018 | 5662 | 0.300 |
Why?
|
Drug Discovery | 3 | 2014 | 1054 | 0.300 |
Why?
|
Receptor, IGF Type 1 | 2 | 2014 | 378 | 0.290 |
Why?
|
Neoplasms | 9 | 2023 | 22083 | 0.280 |
Why?
|
High-Throughput Screening Assays | 2 | 2012 | 934 | 0.280 |
Why?
|
Insulin-Like Growth Factor I | 4 | 2009 | 1929 | 0.270 |
Why?
|
Epigenesis, Genetic | 4 | 2021 | 3782 | 0.270 |
Why?
|
Dexamethasone | 10 | 2021 | 1944 | 0.260 |
Why?
|
Histone-Lysine N-Methyltransferase | 2 | 2024 | 682 | 0.260 |
Why?
|
Leukemia, Myeloid, Acute | 8 | 2021 | 3610 | 0.250 |
Why?
|
Plasma Cells | 3 | 2020 | 599 | 0.250 |
Why?
|
Genes, ras | 3 | 2018 | 653 | 0.250 |
Why?
|
Dose-Response Relationship, Drug | 12 | 2018 | 10759 | 0.240 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 2005 | 192 | 0.240 |
Why?
|
Pyrimidines | 7 | 2018 | 3024 | 0.230 |
Why?
|
Cell Cycle Proteins | 3 | 2014 | 3446 | 0.230 |
Why?
|
Waldenstrom Macroglobulinemia | 3 | 2003 | 1073 | 0.230 |
Why?
|
Genomics | 5 | 2024 | 5806 | 0.230 |
Why?
|
Adenylate Kinase | 1 | 2024 | 102 | 0.230 |
Why?
|
Cell Proliferation | 13 | 2021 | 10425 | 0.230 |
Why?
|
Quinolines | 1 | 2009 | 764 | 0.220 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2004 | 81 | 0.220 |
Why?
|
fms-Like Tyrosine Kinase 3 | 3 | 2013 | 495 | 0.210 |
Why?
|
Up-Regulation | 5 | 2021 | 4116 | 0.210 |
Why?
|
Proto-Oncogene Proteins | 2 | 2012 | 4509 | 0.200 |
Why?
|
Drug Synergism | 8 | 2018 | 1755 | 0.200 |
Why?
|
Remission Induction | 6 | 2021 | 2394 | 0.200 |
Why?
|
Receptors, Purinergic P2 | 1 | 2003 | 150 | 0.200 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2023 | 1640 | 0.200 |
Why?
|
Cell Line | 6 | 2021 | 15598 | 0.200 |
Why?
|
Mice, Nude | 3 | 2021 | 3603 | 0.200 |
Why?
|
Gangliosides | 1 | 2022 | 132 | 0.190 |
Why?
|
Prostatic Neoplasms | 2 | 2020 | 11095 | 0.190 |
Why?
|
B-Lymphocytes | 5 | 2021 | 4748 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2022 | 9267 | 0.190 |
Why?
|
Genes, Overlapping | 1 | 2021 | 36 | 0.190 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 2021 | 321 | 0.190 |
Why?
|
Translocation, Genetic | 2 | 2024 | 1388 | 0.190 |
Why?
|
Eukaryotic Initiation Factor-4E | 1 | 2021 | 112 | 0.180 |
Why?
|
Drug Evaluation, Preclinical | 4 | 2013 | 1337 | 0.180 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2014 | 381 | 0.180 |
Why?
|
Chromosome Deletion | 1 | 2005 | 1387 | 0.180 |
Why?
|
Salvage Therapy | 5 | 2010 | 1264 | 0.170 |
Why?
|
Bone Marrow Cells | 5 | 2013 | 2416 | 0.170 |
Why?
|
Furans | 1 | 2021 | 200 | 0.170 |
Why?
|
Proteomics | 5 | 2021 | 3818 | 0.170 |
Why?
|
Piperazines | 2 | 2009 | 2519 | 0.170 |
Why?
|
Immunity, Innate | 1 | 2012 | 3059 | 0.170 |
Why?
|
Monomeric GTP-Binding Proteins | 1 | 2021 | 200 | 0.170 |
Why?
|
Antigens, Surface | 1 | 2004 | 1608 | 0.170 |
Why?
|
Tumor Burden | 3 | 2011 | 1887 | 0.160 |
Why?
|
IMP Dehydrogenase | 1 | 2018 | 33 | 0.160 |
Why?
|
Immunologic Factors | 4 | 2013 | 1588 | 0.160 |
Why?
|
Drug Therapy, Combination | 4 | 2021 | 6297 | 0.160 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2023 | 1355 | 0.150 |
Why?
|
Flow Cytometry | 4 | 2012 | 5865 | 0.150 |
Why?
|
Pyrroles | 3 | 2018 | 1126 | 0.150 |
Why?
|
Exosomes | 1 | 2023 | 424 | 0.150 |
Why?
|
Mucin-1 | 1 | 2023 | 539 | 0.150 |
Why?
|
Boron Compounds | 2 | 2021 | 182 | 0.150 |
Why?
|
Recurrence | 14 | 2014 | 8466 | 0.150 |
Why?
|
Clinical Trials as Topic | 13 | 2016 | 7996 | 0.150 |
Why?
|
Nuclear Respiratory Factor 1 | 1 | 2017 | 21 | 0.150 |
Why?
|
Biphenyl Compounds | 2 | 2021 | 1003 | 0.150 |
Why?
|
Oncogene Proteins | 2 | 2021 | 718 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 5 | 2023 | 1404 | 0.150 |
Why?
|
Janus Kinases | 3 | 2018 | 249 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2013 | 2453 | 0.150 |
Why?
|
Adjuvants, Immunologic | 1 | 2003 | 1035 | 0.140 |
Why?
|
Arsenicals | 1 | 2017 | 118 | 0.140 |
Why?
|
Glycoproteins | 1 | 2005 | 2207 | 0.140 |
Why?
|
Treatment Outcome | 20 | 2021 | 64591 | 0.140 |
Why?
|
Sulfides | 1 | 2017 | 170 | 0.140 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2021 | 633 | 0.140 |
Why?
|
Nuclear Proteins | 4 | 2017 | 5794 | 0.140 |
Why?
|
Piperidines | 2 | 2018 | 1656 | 0.140 |
Why?
|
Interleukin-6 | 5 | 2010 | 3209 | 0.140 |
Why?
|
Histone Deacetylases | 2 | 2013 | 719 | 0.140 |
Why?
|
Glycine | 2 | 2021 | 665 | 0.130 |
Why?
|
Oxides | 1 | 2017 | 401 | 0.130 |
Why?
|
Drug Repositioning | 1 | 2018 | 233 | 0.130 |
Why?
|
Breast Neoplasms | 3 | 2020 | 20985 | 0.130 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2019 | 478 | 0.120 |
Why?
|
Ovary | 1 | 2019 | 958 | 0.120 |
Why?
|
Cyclophilin A | 1 | 2015 | 58 | 0.120 |
Why?
|
Leukocytes, Mononuclear | 2 | 2012 | 1841 | 0.120 |
Why?
|
Transcription, Genetic | 4 | 2021 | 7597 | 0.120 |
Why?
|
Genome | 1 | 2023 | 1739 | 0.120 |
Why?
|
Peripheral Nervous System Diseases | 3 | 2010 | 710 | 0.120 |
Why?
|
Angiogenesis Inhibitors | 3 | 2011 | 2047 | 0.120 |
Why?
|
Disease Models, Animal | 6 | 2021 | 18216 | 0.120 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2014 | 2423 | 0.120 |
Why?
|
Maximum Tolerated Dose | 3 | 2021 | 882 | 0.120 |
Why?
|
Nuclear Receptor Coactivators | 1 | 2014 | 61 | 0.120 |
Why?
|
GATA2 Transcription Factor | 1 | 2014 | 158 | 0.120 |
Why?
|
Antibodies, Monoclonal | 4 | 2022 | 9176 | 0.110 |
Why?
|
Phenothiazines | 1 | 2014 | 61 | 0.110 |
Why?
|
Prostate-Specific Antigen | 1 | 2004 | 2464 | 0.110 |
Why?
|
Neuroblastoma | 1 | 2022 | 1250 | 0.110 |
Why?
|
Phenylenediamines | 1 | 2014 | 87 | 0.110 |
Why?
|
Syndecan-1 | 2 | 2012 | 163 | 0.110 |
Why?
|
Proteome | 3 | 2018 | 1861 | 0.110 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 1405 | 0.110 |
Why?
|
HEK293 Cells | 2 | 2021 | 4277 | 0.110 |
Why?
|
Teratogens | 1 | 2013 | 117 | 0.110 |
Why?
|
Azepines | 2 | 2014 | 329 | 0.110 |
Why?
|
Adenosine Triphosphatases | 1 | 2017 | 832 | 0.110 |
Why?
|
Immunotherapy | 4 | 2022 | 4649 | 0.110 |
Why?
|
Survival Analysis | 7 | 2019 | 10075 | 0.110 |
Why?
|
Cell Communication | 4 | 2018 | 1652 | 0.110 |
Why?
|
Interleukin-1 Receptor Accessory Protein | 1 | 2012 | 5 | 0.100 |
Why?
|
Disease-Free Survival | 5 | 2012 | 6813 | 0.100 |
Why?
|
Adrenergic beta-2 Receptor Antagonists | 1 | 2012 | 12 | 0.100 |
Why?
|
Penicillium | 1 | 2012 | 22 | 0.100 |
Why?
|
Transcription Factors | 6 | 2021 | 12121 | 0.100 |
Why?
|
Xanthones | 1 | 2012 | 23 | 0.100 |
Why?
|
Chromosomes, Human, Pair 14 | 2 | 2024 | 287 | 0.100 |
Why?
|
Adenosine A2 Receptor Antagonists | 1 | 2012 | 49 | 0.100 |
Why?
|
Receptors, Estrogen | 1 | 2020 | 2204 | 0.100 |
Why?
|
Ikaros Transcription Factor | 1 | 2013 | 232 | 0.100 |
Why?
|
Gene Knockdown Techniques | 4 | 2021 | 1610 | 0.100 |
Why?
|
Protein Phosphatase 2 | 1 | 2014 | 231 | 0.100 |
Why?
|
Clodronic Acid | 1 | 2011 | 59 | 0.100 |
Why?
|
Sulfoxides | 1 | 2011 | 47 | 0.100 |
Why?
|
Leukemia | 2 | 2012 | 1522 | 0.100 |
Why?
|
Sulfonamides | 1 | 2021 | 1973 | 0.100 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2012 | 255 | 0.090 |
Why?
|
Female | 34 | 2021 | 391875 | 0.090 |
Why?
|
Poly(ADP-ribose) Polymerases | 2 | 2011 | 427 | 0.090 |
Why?
|
Cell Compartmentation | 1 | 2012 | 384 | 0.090 |
Why?
|
Bone Diseases | 1 | 2014 | 419 | 0.090 |
Why?
|
Chromatin | 2 | 2020 | 2951 | 0.090 |
Why?
|
G1 Phase | 1 | 2012 | 403 | 0.090 |
Why?
|
Colony-Forming Units Assay | 1 | 2011 | 352 | 0.090 |
Why?
|
Benzoates | 1 | 2012 | 211 | 0.090 |
Why?
|
Peptide Hydrolases | 1 | 2013 | 621 | 0.090 |
Why?
|
Cell Fractionation | 1 | 2011 | 251 | 0.090 |
Why?
|
Hydrazines | 1 | 2012 | 224 | 0.090 |
Why?
|
Inhibitory Concentration 50 | 1 | 2011 | 465 | 0.090 |
Why?
|
Phosphorylation | 5 | 2014 | 8311 | 0.090 |
Why?
|
Quinazolinones | 1 | 2012 | 221 | 0.090 |
Why?
|
Asthenia | 1 | 2010 | 16 | 0.090 |
Why?
|
Blood Coagulation Factors | 1 | 2012 | 365 | 0.090 |
Why?
|
Cell Division | 2 | 2011 | 4461 | 0.090 |
Why?
|
K562 Cells | 1 | 2012 | 642 | 0.090 |
Why?
|
Estrogen Receptor alpha | 1 | 2014 | 581 | 0.090 |
Why?
|
Down-Regulation | 3 | 2013 | 2911 | 0.090 |
Why?
|
Apoptosis Regulatory Proteins | 4 | 2023 | 1135 | 0.090 |
Why?
|
Triazoles | 2 | 2014 | 903 | 0.080 |
Why?
|
Osteolysis | 1 | 2011 | 275 | 0.080 |
Why?
|
Peptides, Cyclic | 2 | 2010 | 392 | 0.080 |
Why?
|
Membrane Glycoproteins | 3 | 2018 | 3701 | 0.080 |
Why?
|
Myelodysplastic Syndromes | 2 | 2012 | 1393 | 0.080 |
Why?
|
Tamoxifen | 1 | 2014 | 964 | 0.080 |
Why?
|
Autophagy | 1 | 2017 | 1319 | 0.080 |
Why?
|
Indoles | 1 | 2017 | 1833 | 0.080 |
Why?
|
Drosophila Proteins | 1 | 2018 | 1698 | 0.080 |
Why?
|
Reactive Oxygen Species | 1 | 2017 | 2137 | 0.080 |
Why?
|
Repressor Proteins | 2 | 2024 | 2978 | 0.080 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2011 | 179 | 0.080 |
Why?
|
Caspase 3 | 1 | 2011 | 729 | 0.080 |
Why?
|
Male | 31 | 2021 | 360035 | 0.080 |
Why?
|
Receptors, Cytokine | 1 | 2009 | 258 | 0.080 |
Why?
|
Small Molecule Libraries | 1 | 2014 | 732 | 0.080 |
Why?
|
Urochordata | 1 | 2008 | 19 | 0.080 |
Why?
|
Mitochondria | 2 | 2012 | 3624 | 0.080 |
Why?
|
Phosphorylcholine | 1 | 2009 | 153 | 0.080 |
Why?
|
Biological Availability | 1 | 2009 | 390 | 0.080 |
Why?
|
Immunoblotting | 2 | 2009 | 1647 | 0.080 |
Why?
|
Receptors, Androgen | 1 | 2014 | 1077 | 0.080 |
Why?
|
Prognosis | 9 | 2019 | 29551 | 0.080 |
Why?
|
Molecular Targeted Therapy | 2 | 2017 | 2805 | 0.080 |
Why?
|
Genome, Human | 1 | 2021 | 4423 | 0.080 |
Why?
|
Endothelial Cells | 2 | 2012 | 3541 | 0.080 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 223 | 0.070 |
Why?
|
Rats, Inbred F344 | 1 | 2009 | 825 | 0.070 |
Why?
|
Seawater | 1 | 2008 | 124 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2020 | 2911 | 0.070 |
Why?
|
Substrate Specificity | 1 | 2012 | 1792 | 0.070 |
Why?
|
Mass Spectrometry | 4 | 2014 | 2189 | 0.070 |
Why?
|
Hedgehog Proteins | 1 | 2012 | 768 | 0.070 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2011 | 563 | 0.070 |
Why?
|
Glucuronidase | 1 | 2009 | 202 | 0.070 |
Why?
|
Osteoclasts | 1 | 2011 | 711 | 0.070 |
Why?
|
Hydroxamic Acids | 2 | 2008 | 481 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2009 | 367 | 0.070 |
Why?
|
Neoplasms, Second Primary | 1 | 2015 | 1051 | 0.070 |
Why?
|
Lymphoma, B-Cell | 1 | 2014 | 940 | 0.070 |
Why?
|
Ubiquitination | 1 | 2012 | 1006 | 0.070 |
Why?
|
Morpholines | 1 | 2010 | 580 | 0.070 |
Why?
|
Diphosphonates | 1 | 2011 | 636 | 0.070 |
Why?
|
Transplantation, Autologous | 1 | 2012 | 2113 | 0.070 |
Why?
|
Caspases | 2 | 2012 | 876 | 0.070 |
Why?
|
Blotting, Western | 2 | 2011 | 5031 | 0.070 |
Why?
|
Purines | 1 | 2010 | 605 | 0.070 |
Why?
|
Monocytes | 2 | 2012 | 2572 | 0.070 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2020 | 2058 | 0.070 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2013 | 1766 | 0.070 |
Why?
|
Fibrinogen | 1 | 2009 | 889 | 0.070 |
Why?
|
Drug Interactions | 1 | 2011 | 1415 | 0.070 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1741 | 0.070 |
Why?
|
Adenosine Triphosphate | 1 | 2012 | 1989 | 0.070 |
Why?
|
Renal Insufficiency | 1 | 2012 | 809 | 0.070 |
Why?
|
Staurosporine | 3 | 2013 | 242 | 0.060 |
Why?
|
Proteins | 1 | 2021 | 6033 | 0.060 |
Why?
|
Biomimetic Materials | 1 | 2007 | 172 | 0.060 |
Why?
|
Oncogenes | 2 | 2018 | 1223 | 0.060 |
Why?
|
Transplantation, Heterologous | 2 | 2004 | 2385 | 0.060 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2009 | 487 | 0.060 |
Why?
|
Mutant Proteins | 1 | 2007 | 491 | 0.060 |
Why?
|
Benzodiazepines | 1 | 2011 | 1130 | 0.060 |
Why?
|
Pyrazoles | 2 | 2014 | 2007 | 0.060 |
Why?
|
Transcriptional Activation | 1 | 2011 | 1753 | 0.060 |
Why?
|
Stress, Physiological | 1 | 2012 | 1400 | 0.060 |
Why?
|
Chemokines, CXC | 1 | 2007 | 422 | 0.060 |
Why?
|
Leukemia, Plasma Cell | 1 | 2005 | 46 | 0.060 |
Why?
|
Administration, Oral | 2 | 2011 | 4010 | 0.060 |
Why?
|
CpG Islands | 1 | 2009 | 1225 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2008 | 3777 | 0.060 |
Why?
|
Drug Combinations | 1 | 2011 | 2043 | 0.060 |
Why?
|
Ovarian Neoplasms | 2 | 2019 | 4879 | 0.060 |
Why?
|
Protein Structure, Tertiary | 1 | 2011 | 3792 | 0.060 |
Why?
|
Bone Density Conservation Agents | 1 | 2011 | 795 | 0.060 |
Why?
|
Encephalomyelitis, Autoimmune, Experimental | 1 | 2009 | 822 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2016 | 3576 | 0.060 |
Why?
|
Time Factors | 4 | 2014 | 39947 | 0.060 |
Why?
|
Hematopoietic Stem Cells | 3 | 2012 | 3396 | 0.060 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 4567 | 0.060 |
Why?
|
T-Lymphocytes | 2 | 2013 | 10188 | 0.060 |
Why?
|
Iron | 1 | 2012 | 1787 | 0.060 |
Why?
|
Biological Therapy | 1 | 2005 | 141 | 0.050 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 2024 | 375 | 0.050 |
Why?
|
Cell Differentiation | 3 | 2016 | 11526 | 0.050 |
Why?
|
Histones | 1 | 2013 | 2577 | 0.050 |
Why?
|
Homeodomain Proteins | 1 | 2012 | 2413 | 0.050 |
Why?
|
Hematopoiesis | 1 | 2012 | 2049 | 0.050 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2003 | 283 | 0.050 |
Why?
|
Receptors, Purinergic P2X7 | 1 | 2003 | 85 | 0.050 |
Why?
|
Retinal Neoplasms | 1 | 2005 | 146 | 0.050 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2023 | 95 | 0.050 |
Why?
|
Receptors, Notch | 2 | 2020 | 743 | 0.050 |
Why?
|
Sequence Analysis, DNA | 1 | 2013 | 4735 | 0.050 |
Why?
|
Survival Rate | 3 | 2012 | 12698 | 0.050 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2005 | 584 | 0.050 |
Why?
|
Protein Kinases | 1 | 2009 | 1607 | 0.050 |
Why?
|
Retinoblastoma | 1 | 2005 | 317 | 0.050 |
Why?
|
bcl-X Protein | 1 | 2023 | 410 | 0.050 |
Why?
|
Cytokines | 3 | 2013 | 7377 | 0.050 |
Why?
|
HL-60 Cells | 2 | 2012 | 363 | 0.050 |
Why?
|
Blood Proteins | 1 | 2007 | 1174 | 0.050 |
Why?
|
Animals, Genetically Modified | 2 | 2018 | 1561 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 12653 | 0.050 |
Why?
|
Protein Array Analysis | 1 | 2003 | 400 | 0.050 |
Why?
|
Mitochondrial Proteins | 1 | 2007 | 979 | 0.050 |
Why?
|
Thiazoles | 2 | 2012 | 1513 | 0.050 |
Why?
|
Fluorescence | 1 | 2003 | 756 | 0.050 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 151 | 0.050 |
Why?
|
Luminescent Proteins | 1 | 2003 | 836 | 0.050 |
Why?
|
Membrane Potential, Mitochondrial | 2 | 2012 | 293 | 0.050 |
Why?
|
Peptide Fragments | 2 | 2011 | 5105 | 0.050 |
Why?
|
Carbon | 1 | 2024 | 665 | 0.050 |
Why?
|
Bone and Bones | 1 | 2011 | 2566 | 0.040 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 1745 | 0.040 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2021 | 410 | 0.040 |
Why?
|
DNA-Binding Proteins | 3 | 2020 | 9598 | 0.040 |
Why?
|
Cell Death | 2 | 2017 | 1664 | 0.040 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2009 | 2860 | 0.040 |
Why?
|
Neoplasm Transplantation | 1 | 2003 | 2014 | 0.040 |
Why?
|
Microdissection | 1 | 2019 | 151 | 0.040 |
Why?
|
Mutation | 3 | 2013 | 30025 | 0.040 |
Why?
|
Cyclin D1 | 1 | 2021 | 451 | 0.040 |
Why?
|
Neoplasm Staging | 3 | 2015 | 11096 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2003 | 1062 | 0.040 |
Why?
|
Thioredoxins | 1 | 2020 | 201 | 0.040 |
Why?
|
Prodrugs | 1 | 2021 | 261 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2005 | 3486 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2005 | 2509 | 0.040 |
Why?
|
Drosophila melanogaster | 2 | 2018 | 1709 | 0.040 |
Why?
|
Gene Silencing | 1 | 2005 | 1509 | 0.040 |
Why?
|
Carcinoma | 1 | 2009 | 2328 | 0.040 |
Why?
|
Antigen Presentation | 1 | 2023 | 1254 | 0.040 |
Why?
|
Models, Biological | 3 | 2012 | 9462 | 0.040 |
Why?
|
Green Fluorescent Proteins | 1 | 2003 | 2060 | 0.040 |
Why?
|
Germinal Center | 1 | 2021 | 380 | 0.040 |
Why?
|
Vesicle-Associated Membrane Protein 2 | 1 | 2017 | 17 | 0.040 |
Why?
|
Macrophages | 1 | 2012 | 5764 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2021 | 6525 | 0.040 |
Why?
|
Binding Sites | 2 | 2021 | 6042 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 3541 | 0.040 |
Why?
|
Treatment Failure | 1 | 2004 | 2642 | 0.040 |
Why?
|
MicroRNAs | 1 | 2013 | 3796 | 0.040 |
Why?
|
STAT Transcription Factors | 1 | 2018 | 188 | 0.040 |
Why?
|
Transgenes | 1 | 2021 | 1009 | 0.040 |
Why?
|
Gene Expression Regulation | 4 | 2013 | 11900 | 0.030 |
Why?
|
Precancerous Conditions | 1 | 2003 | 978 | 0.030 |
Why?
|
Middle Aged | 16 | 2021 | 220382 | 0.030 |
Why?
|
Prednisone | 2 | 2012 | 1564 | 0.030 |
Why?
|
Ligands | 1 | 2023 | 3270 | 0.030 |
Why?
|
Drug Design | 1 | 2021 | 1050 | 0.030 |
Why?
|
Aged | 13 | 2021 | 168840 | 0.030 |
Why?
|
Transfection | 1 | 2003 | 5776 | 0.030 |
Why?
|
Prostatectomy | 1 | 2004 | 1821 | 0.030 |
Why?
|
Forecasting | 1 | 2004 | 2925 | 0.030 |
Why?
|
Unfolded Protein Response | 1 | 2017 | 234 | 0.030 |
Why?
|
DNA Methylation | 1 | 2009 | 4383 | 0.030 |
Why?
|
Cluster Analysis | 2 | 2012 | 2711 | 0.030 |
Why?
|
Melphalan | 2 | 2010 | 420 | 0.030 |
Why?
|
Plasmacytoma | 1 | 2015 | 171 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 857 | 0.030 |
Why?
|
Perphenazine | 1 | 2014 | 33 | 0.030 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2014 | 164 | 0.030 |
Why?
|
Combined Modality Therapy | 3 | 2013 | 8522 | 0.030 |
Why?
|
Carrier Proteins | 1 | 2007 | 4936 | 0.030 |
Why?
|
Rhodamine 123 | 1 | 2013 | 37 | 0.030 |
Why?
|
Naphthoquinones | 1 | 2013 | 58 | 0.030 |
Why?
|
Osteogenesis | 1 | 2020 | 1273 | 0.030 |
Why?
|
Genetic Variation | 1 | 2009 | 6570 | 0.030 |
Why?
|
Pigmentation | 1 | 2014 | 144 | 0.030 |
Why?
|
Kinetics | 1 | 2021 | 6377 | 0.030 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2013 | 57 | 0.030 |
Why?
|
Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2013 | 93 | 0.030 |
Why?
|
RNA, Small Interfering | 2 | 2014 | 3428 | 0.030 |
Why?
|
Dopamine Antagonists | 1 | 2014 | 288 | 0.030 |
Why?
|
Fatigue | 2 | 2010 | 1550 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2004 | 5236 | 0.030 |
Why?
|
Chromatography, Affinity | 1 | 2014 | 532 | 0.030 |
Why?
|
Biomedical Research | 1 | 2008 | 3421 | 0.030 |
Why?
|
Jurkat Cells | 1 | 2014 | 739 | 0.030 |
Why?
|
Rats | 1 | 2009 | 23712 | 0.030 |
Why?
|
Polymorphism, Genetic | 1 | 2003 | 4287 | 0.030 |
Why?
|
Cell Adhesion | 2 | 2013 | 3088 | 0.030 |
Why?
|
X-Linked Inhibitor of Apoptosis Protein | 1 | 2012 | 60 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2010 | 4849 | 0.020 |
Why?
|
Costa Rica | 1 | 2012 | 180 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2017 | 2821 | 0.020 |
Why?
|
U937 Cells | 1 | 2012 | 261 | 0.020 |
Why?
|
Benzothiazoles | 1 | 2013 | 247 | 0.020 |
Why?
|
Leukemia, Experimental | 1 | 2012 | 225 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2017 | 1075 | 0.020 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2014 | 359 | 0.020 |
Why?
|
Aged, 80 and over | 6 | 2014 | 58859 | 0.020 |
Why?
|
Incidence | 3 | 2015 | 21322 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2014 | 641 | 0.020 |
Why?
|
Pyrimidinones | 1 | 2014 | 384 | 0.020 |
Why?
|
STAT5 Transcription Factor | 1 | 2012 | 264 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2006 | 15257 | 0.020 |
Why?
|
Drug Delivery Systems | 2 | 2017 | 2224 | 0.020 |
Why?
|
Receptors, Thrombopoietin | 1 | 2012 | 160 | 0.020 |
Why?
|
Interferon-gamma | 2 | 2013 | 3157 | 0.020 |
Why?
|
Lymphocyte Activation | 2 | 2013 | 5491 | 0.020 |
Why?
|
Area Under Curve | 1 | 2014 | 1633 | 0.020 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 441 | 0.020 |
Why?
|
Risk | 2 | 2015 | 9605 | 0.020 |
Why?
|
Antigens, CD34 | 1 | 2012 | 658 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2017 | 1485 | 0.020 |
Why?
|
Adult | 10 | 2021 | 220781 | 0.020 |
Why?
|
beta Catenin | 1 | 2015 | 1040 | 0.020 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2013 | 617 | 0.020 |
Why?
|
Phenylurea Compounds | 1 | 2013 | 528 | 0.020 |
Why?
|
Permeability | 1 | 2011 | 721 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2006 | 4355 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2010 | 191 | 0.020 |
Why?
|
Lentivirus | 1 | 2012 | 508 | 0.020 |
Why?
|
Cysteine | 1 | 2014 | 892 | 0.020 |
Why?
|
Phenotype | 2 | 2021 | 16585 | 0.020 |
Why?
|
Nuclear Magnetic Resonance, Biomolecular | 1 | 2012 | 509 | 0.020 |
Why?
|
Benzimidazoles | 1 | 2014 | 855 | 0.020 |
Why?
|
Sensation Disorders | 1 | 2010 | 160 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2013 | 800 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2018 | 2444 | 0.020 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 687 | 0.020 |
Why?
|
Clone Cells | 1 | 2012 | 1660 | 0.020 |
Why?
|
Multiprotein Complexes | 1 | 2015 | 1119 | 0.020 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2012 | 651 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2012 | 727 | 0.020 |
Why?
|
Biological Transport | 1 | 2013 | 2090 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2021 | 22121 | 0.020 |
Why?
|
Epigenomics | 1 | 2014 | 940 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2018 | 2803 | 0.020 |
Why?
|
Neoplasm Proteins | 2 | 2015 | 3610 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2021 | 9533 | 0.020 |
Why?
|
HSP70 Heat-Shock Proteins | 1 | 2010 | 398 | 0.020 |
Why?
|
Enhancer Elements, Genetic | 1 | 2014 | 1363 | 0.020 |
Why?
|
Polyneuropathies | 1 | 2009 | 137 | 0.020 |
Why?
|
Central Nervous System | 1 | 2015 | 1337 | 0.020 |
Why?
|
Molecular Structure | 1 | 2012 | 1875 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2012 | 1008 | 0.020 |
Why?
|
Mesenchymal Stem Cells | 1 | 2018 | 1636 | 0.020 |
Why?
|
Estradiol | 1 | 2014 | 1935 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2011 | 2217 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39078 | 0.020 |
Why?
|
Blood Coagulation | 1 | 2012 | 1154 | 0.020 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2007 | 196 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2018 | 3661 | 0.020 |
Why?
|
Janus Kinase 2 | 1 | 2009 | 544 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2013 | 12785 | 0.020 |
Why?
|
Risk Management | 1 | 2010 | 557 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 2010 | 496 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2017 | 3108 | 0.020 |
Why?
|
Nanoparticles | 1 | 2017 | 1953 | 0.020 |
Why?
|
STAT3 Transcription Factor | 1 | 2010 | 870 | 0.020 |
Why?
|
Disease Progression | 3 | 2011 | 13484 | 0.020 |
Why?
|
Immunosuppressive Agents | 2 | 2009 | 4168 | 0.020 |
Why?
|
Genetic Testing | 1 | 2018 | 3535 | 0.020 |
Why?
|
RNA-Binding Proteins | 1 | 2014 | 1897 | 0.020 |
Why?
|
CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2005 | 46 | 0.020 |
Why?
|
Fluorescent Dyes | 1 | 2013 | 1900 | 0.020 |
Why?
|
Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2005 | 58 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2011 | 1771 | 0.010 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2012 | 1248 | 0.010 |
Why?
|
Caspase 8 | 1 | 2005 | 189 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2003 | 7424 | 0.010 |
Why?
|
Fas Ligand Protein | 1 | 2005 | 215 | 0.010 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2015 | 5663 | 0.010 |
Why?
|
Prospective Studies | 4 | 2012 | 54339 | 0.010 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2005 | 192 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3800 | 0.010 |
Why?
|
Immunotherapy, Adoptive | 1 | 2013 | 1463 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2015 | 3469 | 0.010 |
Why?
|
Risk Reduction Behavior | 1 | 2010 | 1112 | 0.010 |
Why?
|
Child | 3 | 2022 | 80086 | 0.010 |
Why?
|
Biopsy | 1 | 2015 | 6765 | 0.010 |
Why?
|
Cell Movement | 1 | 2015 | 5198 | 0.010 |
Why?
|
Azacitidine | 1 | 2005 | 336 | 0.010 |
Why?
|
Base Sequence | 1 | 2014 | 12449 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 2012 | 2819 | 0.010 |
Why?
|
Pharmacogenetics | 1 | 2006 | 675 | 0.010 |
Why?
|
Cyclins | 1 | 2005 | 594 | 0.010 |
Why?
|
Cysteine Proteinase Inhibitors | 1 | 2003 | 188 | 0.010 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 1549 | 0.010 |
Why?
|
Haplotypes | 1 | 2009 | 2773 | 0.010 |
Why?
|
Zebrafish | 1 | 2014 | 3002 | 0.010 |
Why?
|
Antigens, CD | 1 | 2013 | 4000 | 0.010 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2005 | 237 | 0.010 |
Why?
|
Autoimmunity | 1 | 2009 | 1355 | 0.010 |
Why?
|
Safety | 1 | 2006 | 1150 | 0.010 |
Why?
|
Dendritic Cells | 1 | 2013 | 2725 | 0.010 |
Why?
|
Models, Statistical | 1 | 2016 | 5078 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2015 | 11070 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2009 | 4108 | 0.010 |
Why?
|
Anemia | 1 | 2010 | 1508 | 0.010 |
Why?
|
Head and Neck Neoplasms | 1 | 2015 | 2891 | 0.010 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2004 | 1125 | 0.010 |
Why?
|
Subtraction Technique | 1 | 2003 | 511 | 0.010 |
Why?
|
Pyridines | 1 | 2012 | 2868 | 0.010 |
Why?
|
Mutation, Missense | 1 | 2009 | 2571 | 0.010 |
Why?
|
Antibodies, Neutralizing | 1 | 2010 | 1942 | 0.010 |
Why?
|
Acetylation | 1 | 2003 | 1054 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2009 | 2163 | 0.010 |
Why?
|
Venous Thromboembolism | 1 | 2012 | 1863 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2012 | 17639 | 0.010 |
Why?
|
Medical Oncology | 1 | 2011 | 2318 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6475 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2016 | 20078 | 0.010 |
Why?
|
Protein Binding | 1 | 2009 | 9340 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2004 | 1891 | 0.010 |
Why?
|
Venous Thrombosis | 1 | 2006 | 1297 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2012 | 14397 | 0.010 |
Why?
|
Doxorubicin | 1 | 2002 | 2215 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14661 | 0.010 |
Why?
|
Pain | 1 | 2010 | 5075 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2005 | 2870 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2011 | 7380 | 0.010 |
Why?
|
Genotype | 1 | 2009 | 12976 | 0.010 |
Why?
|
Prevalence | 1 | 2011 | 15698 | 0.010 |
Why?
|
Logistic Models | 1 | 2009 | 13240 | 0.010 |
Why?
|
DNA Damage | 1 | 2002 | 2441 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2009 | 10180 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2009 | 22097 | 0.010 |
Why?
|
Cohort Studies | 1 | 2012 | 41366 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2009 | 15867 | 0.010 |
Why?
|
Risk Factors | 1 | 2011 | 74055 | 0.000 |
Why?
|